Join Gold Sponsor BioMarin for an evening reception as they announce their 2025 Golden Ticket winner!
Six innovative startups will pitch for the chance to win a Golden Ticket, helping one company further their research at LabCentral and the opportunity to accelerate their groundbreaking research.
Before the pitches, hear directly from leaders at BioMarin as they share insights into the company's vision, scientific focus areas, and approach to partnering with early-stage biotech innovators. Come for the science, stay for the competition, and find out who will take home the 2025 Golden Ticket!
Agenda
4:30PM Registration
5:00PM BioMarin Presentation
5:30PM Finalist Pitches and Winner Announcement
6:00PM Networking Reception
4:30 PM
5:00 PM
5:30 PM
6:00 PM
Registration
BioMarin Presentation
Finalist Pitches and Winner Announcement
Networking Reception
Finalists
AcousticaBio is focused on solving the greatest challenges in the delivery of novel therapeutics by using proprietary fluid processing technology. With strong in-vitro and in-vivo safety and efficacy data, they have built collaborations with leading global biopharmaceutical companies.
Amaryllis Therapeutics
Founded by serial entrepreneurs from Flagship, Harvard and MIT, Amaryllis Therapeutics (ATx) has developed a novel BBB-crossing peptide enabling small molecules, antibodies, and nucleic acids delivery to the brain. With Alzheimer's as the north star, ATx has a long pipeline of drug targets, repurposing FDA-approved drugs w/ significant delivery improvement (e.g., 40x for peptides, 200x for antibodies, etc.). ATx is beginning its IND enabling NHP studies and in active discussion with potential pharma partners.
Nucyrna aims to address the unmet medical needs in neurodegenerative diseases with their next-gen RNA-targeting technology.
Riboway Therapeutics specialize in controlling how proteins are made by targeting RNA. Their smart RNA-targeting technology enables them to upregulate, downregulate, activate, or inhibit target proteins, depending on therapeutic needs. This flexibility is driven by their AI-based platform that decodes RNA regulation to identify druggable angles.
Sutol Bio
SUTOL bio is developing a next-generation monthly oral capsule platform.
Transit Therapeutics
Transit Therapeutics focuses on protein-free trans-splicing of pre-mRNA with technology out of MIT/Harvard and UC Berkeley/Arc Institute and a focus on CNS and other target organs.
BioMarin Featured Speakers
Pooja Agarwal
Head of Therapeutic Modalities and Operations
Stuart Bunting
GVP, Head of Research
Amita Gupta, Ph.D
Business Development Lead
Chieze Ibeneche-Nnewine, Ph.D
Senior Director, Business Development and Corporate Strategy
Justin Ichida
VP, Head of Neuroscience Research
Jan Lui
Associate Director, Neuroscience